Main Administrative Core

主要行政核心

• 批准号: 10428601
• 负责人: ANNE M MURRAY
• 金额: $ 411.84万
• 依托单位: HENNEPIN HEALTHCARE RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-07-15 至 2024-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10428601
• 关键词: Accreditation; African American population; Age; Aging; Alzheimer' s Disease; Alzheimer' s disease related dementia; Area; Aspirin; Australia; Cardiovascular Diseases; Cessation of life; Characteristics; Classification; Clinical; Clinical Data; Cognitive; Communication; Contracts; Country; Coupled; Data; Data Linkages; Data Set; Dementia; Documentation; Dose; Elderly; Ensure; Ethics; Event; Exposure to; Female; Fostering; Funding; Gender; Goals; Grant; Health; Heart failure; Hemorrhage; Hispanic Populations; Impaired cognition; Infrastructure; International; Intervention; Knowledge; Leadership; Life; Logistics; Longevity; Longitudinal Studies; Longitudinal cohort study; Malignant Neoplasms; Mediation; Minority; Monitor; Outcome; Participant; Persons; Procedures; Randomized; Registries; Research; Resources; Site; Societies; Standardization; Stroke; Testing; Training; United States; adjudication; aged; aging population; cancer prevention; cohort; disability; experience; follow-up; insight; nonalzheimer dementia; operation; physically handicapped; primary endpoint; secondary endpoint; success

ASPREE-XT BI-NATIONAL ADMINISTRATIVE CORE – SUMMARY / ABSTRACT The ASPirin in Reducing Events in the Elderly (ASPREE) study successfully established a cohort of 19,114 healthy older adults in the U.S. and Australia who were free of Alzheimer’s disease and related dementias (ADRD), cardiovascular disease, and significant physical disability at baseline, and tested whether the exposure to 5 years of low-dose aspirin (LDA) would prolong dementia-free and disability-free survival. Although the intervention period has ended, the establishment of this large and diverse cohort, coupled with unprecedented findings from the intervention period, has created a rare opportunity for continued surveillance of important health outcomes and the antecedents that jeopardize disability-free survival in this aging population; especially ADRD and cancer. Personal health information will be collected annually from participants, and major clinical events will be confirmed through case documentation prepared for expert adjudication of ADRD (and sub-type classification into Alzheimer’s disease and non- ADRD), cancer (incident, metastatic, type, stage and death), and other key health outcomes including death. Observational follow-up of large, long-term aging studies such as ASPREE benefit from continuity, experience and leadership with ADRD expertise. In this funding request, the ASPREE leadership team proposes to extend follow-up of the participants in both the U.S. and Australia for an additional five years (i.e., ‘ASPREE-XT’), which will greatly enrich an already unique, and highly valuable international research asset focused on prolonging healthy independent life in the elderly, free of dementia and disability. The infrastructure needed to accomplish this will rely on the continuity, leadership, and experience of the U.S. and Australian Coordinating Centers that have proven their success in the ASPREE trial through the exemplary study conduct and completion. This includes bi-national standardized training and accreditation to ensure the consistent administration of the annual cognitive battery and triggered dementia assessments which include the Alzheimer's Disease Assessment Scale cognitive subscale. The Bi-National Administrative Core will deploy the infrastructure and governance necessary to accomplish the aims of the ASPREE-XT longitudinal cohort study, including to understand the legacy effects of low dose aspirin on cognitive decline, ADRD, disability and cancer prevention. The overarching goal of the Bi-National Administrative Core is to foster the dynamic exchange of information, ideas, and data arising from all Cores to provide insight into factors that may extend dementia-free and disability-free survival of older adults.

ASPREE-XT 两国行政核心 – 摘要/摘要 阿司匹林减少老年人事件 (ASPREE) 研究成功建立了一个由 19,114 名来自美国和澳大利亚的健康老年人组成的队列，这些老年人在基线时没有阿尔茨海默氏病和相关痴呆症 (ADRD)、心血管疾病和明显的身体残疾，并测试了服用 5 年低剂量阿司匹林 (LDA) 是否会延长无痴呆症和无残疾的生存期。尽管干预期已经结束，但这个庞大而多样化的队列的建立，加上干预期前所未有的发现，为继续监测重要的健康结果和危及老龄化人口无残疾生存的前因创造了难得的机会；尤其是 ADRD 和癌症。每年都会从参与者那里收集个人健康信息，重大临床事件将通过为 ADRD（以及阿尔茨海默病和非 ADRD 亚型分类）、癌症（发病、转移、类型、分期和死亡）以及包括死亡在内的其他关键健康结果的专家裁决而准备的病例文件来确认。 ASPREE 等大型长期衰老研究的观​​察性随访受益于 ADRD 专业知识的连续性、经验和领导力。在本次资助请求中，ASPREE 领导团队建议将美国和澳大利亚参与者的随访时间再延长五年（即“ASPREE-XT”），这将极大地丰富本已独特且极具价值的国际研究资产，该资产专注于延长老年人的健康独立生活，避免痴呆和残疾。实现这一目标所需的基础设施将依赖于美国和澳大利亚协调中心的连续性、领导力和经验，这些协调中心通过模范的研究实施和完成，证明了 ASPREE 试验的成功。这包括两国标准化培训和认证，以确保年度认知电池和触发痴呆症评估的一致管理，其中包括阿尔茨海默病评估量表认知子量表。两国行政核心将部署必要的基础设施和治理，以实现 ASPREE-XT 纵向队列研究的目标，包括了解低剂量阿司匹林对认知能力下降、ADRD、残疾和癌症预防的遗留影响。两国行政核心的总体目标是促进所有核心的信息、想法和数据的动态交流，以深入了解可能延长老年人无痴呆和无残疾生存期的因素。